<DOC>
	<DOC>NCT02220244</DOC>
	<brief_summary>The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the visual improvement of patients suffering from chronic visual loss resulting from multiple sclerosis related optic neuritis.</brief_summary>
	<brief_title>Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<criteria>1. Diagnosis criteria of MS fulfilling revised Mc Donald criteria (2010) 2. Unior bilateral optic neuropathy with worst eye VAâ‰¤ 5/10 confirmed at 6 months 3. Worsening of visual acuity during the last three years 4. Informed consent prior to any study procedure 5. Patient aged 1875 years 1. Optic neuritis relapse within the three months before inclusion 2. Normal RNFL at OCT 3. Presence of other ocular pathology (glaucoma, cataract, retinopathy, anterior uveitis, myopia&gt;7 dioptrics, intraocular pressure&gt;20 mm Hg, amblyopia, retinal or optic head abnormalities (drusen, tilted disc) 4. Bilateral visual acuity &lt;1/20 5. Visual impairment caused by ocular flutter or nystagmus 6. Pregnancy or childbearing potential woman without contraception 7. Any general chronic handicapping disease other than MS 8. New treatment introduced less than 3 months prior to inclusion or less than 1 month for Fampridine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>multiple sclerosis (MS)</keyword>
	<keyword>optic neuritis</keyword>
	<keyword>visual defect</keyword>
	<keyword>visual loss</keyword>
	<keyword>relapsing remitting multiple sclerosis (RRMS)</keyword>
	<keyword>primary progressive multiple sclerosis (PPMS)</keyword>
	<keyword>secondary progressive multiple sclerosis (SPMS)</keyword>
</DOC>